Literature DB >> 15383286

Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase.

Dimitrios A Skoufias1, Françoise B Lacroix, Paul R Andreassen, Leslie Wilson, Robert L Margolis.   

Abstract

DNA damage by double-strand breaks induces arrest during interphase in mammalian cells. It is not clear whether DNA damage can arrest cells in mitosis. We show here that three human cell lines, HeLa, U2OS, and HCT116, do not delay in mitosis in response to double-strand breaks induced during mitosis by gamma irradiation or by adriamycin. Durable arrest at metaphase occurs, however, with ICRF-193, a topoisomerase II inhibitor that does not damage DNA. Arrest with ICRF-193 is not accompanied by recruitment of Mad2 or Bub1 to kinetochores, nor by phosphorylation of the histone H2AX, indicating arrest by ICRF-193 is not due to activation of the spindle assembly checkpoint, nor is it a response to DNA damage. VP-16, another decatenation inhibitor, induces metaphase arrest only at concentrations well above those that induce DNA damage. We conclude that decatenation failure, but not DNA damage, creates metaphase arrest in mammalian cells. Copyright 2004 Cell Press

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383286     DOI: 10.1016/j.molcel.2004.08.018

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  55 in total

1.  Mammalian Fbh1 is important to restore normal mitotic progression following decatenation stress.

Authors:  Corentin Laulier; Anita Cheng; Nick Huang; Jeremy M Stark
Journal:  DNA Repair (Amst)       Date:  2010-04-24

2.  Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells.

Authors:  Ruth E Gonzalez; Chang-Uk Lim; Kelly Cole; Christine Hanko Bianchini; Gary P Schools; Brian E Davis; Ikuo Wada; Igor B Roninson; Eugenia V Broude
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

3.  BRCA1 associates with the inactive X chromosome in late S-phase, coupled with transient H2AX phosphorylation.

Authors:  Brian P Chadwick; Timothy F Lane
Journal:  Chromosoma       Date:  2005-11-15       Impact factor: 4.316

4.  Topoisomerase II-DNA complexes trapped by ICRF-193 perturb chromatin structure.

Authors:  Thomas Germe; Olivier Hyrien
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

5.  Depletion of topoisomerase IIalpha leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads.

Authors:  Jennifer M Spence; Hui Hui Phua; Walter Mills; Adam J Carpenter; Andrew C G Porter; Christine J Farr
Journal:  J Cell Sci       Date:  2007-10-23       Impact factor: 5.285

Review 6.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 7.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

8.  Discovery of cellular regulation by protein degradation.

Authors:  Alexander Varshavsky
Journal:  J Biol Chem       Date:  2008-08-15       Impact factor: 5.157

Review 9.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

10.  A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin.

Authors:  Catherine A Andrews; Amit C Vas; Brian Meier; Juan F Giménez-Abián; Laura A Díaz-Martínez; Julie Green; Stacy L Erickson; Kristyn E Vanderwaal; Wei-Shan Hsu; Duncan J Clarke
Journal:  Genes Dev       Date:  2006-05-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.